# Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Study · id `cardio:ct-nct03664180` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03664180](<https://clinicaltrials.gov/study/NCT03664180>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03664180

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2989 participants.

## Technical summary

Registry record NCT03664180. Randomized; triple masking; primary purpose treatment. Start 2019-01-11 (actual); primary completion 2022-11-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2989 participants (enrolled count; ClinicalTrials.gov record NCT03664180, source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)
- Started: 2019-01-11 (actual) (ClinicalTrials.gov record NCT03664180, source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)
- Primary completion: 2022-11-23 (actual) (ClinicalTrials.gov record NCT03664180, source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)
- Completion: 2022-11-23 (actual) (ClinicalTrials.gov record NCT03664180, source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03664180, source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03664180-2023-05-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
- Acronym: RIGHT
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): Bivalirudin
- Intervention (Drug): Enoxaparin
- Intervention (Drug): Unfractionated heparin
- Intervention (Drug): Bivalirudin placebo
- Intervention (Drug): Enoxaparin placebo syringe
- Intervention (Drug): Unfractionated heparin placebo
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER
- Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator class: OTHER
- Collaborator: Groupe Hospitalier Pitie-Salpetriere
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)
- Registry lists this organization as a collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)
- Registry lists this organization as a collaborator: Groupe Hospitalier Pitie-Salpetriere (`cardio:org-groupe-hospitalier-pitie-salpetriere`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial (`cardio:pubmed-38406848`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2d95261b8b9a92df962b79bb30ac587dc471768d83edd039bef3313a1649e373
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
